Gastrointestinal transit and release of 5‐aminosalicylic acid from 153Sm‐labelled mesalazine pellets vs. tablets in male healthy volunteers
- 2 May 2003
- journal article
- clinical trial
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 17 (9), 1163-1169
- https://doi.org/10.1046/j.1365-2036.2003.01564.x
Abstract
Background : Mesalazine (5‐aminosalicylic acid)‐containing formulations, designed to optimize drug delivery to the ileo‐caecal region, represent a cornerstone in the treatment of inflammatory bowel diseases. Aim : To test, by means of pharmaco‐scintigraphy, whether novel mesalazine‐containing pellets release 5‐aminosalicylic acid in the same target region as mesalazine tablets (Salofalk). Methods : Fourteen healthy male volunteers received a single dose of either pellets or tablets containing 500 mg of mesalazine and 2 mg of 152Sm2O3 with a 1‐week washout period. The gastrointestinal transit of 153Sm, incorporated into the formulations, was followed by gamma‐scintigraphy. Mesalazine release was verified by assessing 5‐aminosalicylic acid plasma pharmacokinetics. Results : The formulations reached the ileo‐caecal target region almost at the same time (3.3 ± 1 and 3.8 ± 1 h for pellets and tablets, respectively). Plasma 5‐aminosalicylic acid tmax values were comparable and corresponded to the time during which the formulations were located in the target region. Plasma AUC values were significantly lower for pellets, which might be explained by a more prolonged release of 5‐aminosalicylic acid. Conclusions : Novel mesalazine pellets and Salofalk tablets release active 5‐aminosalicylic acid in the same target region and pass through the gastrointestinal tract under fasting conditions in healthy volunteers in a comparable time. From a comparison of in vitro dissolution and plasma concentration data, a slower and more prolonged release of 5‐aminosalicylic acid from pellets is suggested.Keywords
This publication has 25 references indexed in Scilit:
- Clinical Pharmacokinetics of Slow Release MesalazineClinical Pharmacokinetics, 2000
- Dose finding study of the efficacy and safety of newly developed 5-ASA containing pellets in patients with active ulcerative colitisGastroenterology, 2000
- Delivery and fate of oral mesalamine microgranules within the human small intestineGastroenterology, 1995
- Localization of Drug Release Sites from an Oral Sustained‐Release Formulation of 5‐ASA (Pentasa®) in the Gastrointestinal Tract Using Gamma ScintigraphyThe Journal of Clinical Pharmacology, 1993
- Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's diseaseDigestive Diseases and Sciences, 1992
- Scintigraphic and pharmacokinetic assessment of a multiparticulate sustained release formulation of diltiazemInternational Journal of Pharmaceutics, 1991
- Evaluation of an enteric‐coated naproxen pellet formulationAlimentary Pharmacology & Therapeutics, 1991
- Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion.Gut, 1990
- Evaluation of an enteric‐coated delayed‐release 5‐aminosalicylic acid tablet in patients with inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 1987
- Gastrointestinal transit of an enteric‐coated delayed‐release 5‐aminosalicylic acid tabletAlimentary Pharmacology & Therapeutics, 1987